Nd:YAG laser vs topical control
Modified HS‐LASI score after 3 months · participants with hidradenitis suppurativa
1 finding from 1 review
- no estimate extracted1 study · 50 participantsVery low
Findings
What do systematic reviews say?
1,133 questions · 1,153 findings · 36 reviews · Skin
No studies found 407 · 35.3%GRADE not reported 90 · 7.8%Very low 183 · 15.9%Low 209 · 18.1%Moderate 211 · 18.3%High 53 · 4.6%
Nd:YAG laser vs topical control
Modified HS‐LASI score after 3 months ‐ axilla · participants with hidradenitis suppurativa
1 finding from 1 review
- no estimate extracted1 study · 20 participantsVery low
Nd:YAG laser vs topical control
Modified HS‐LASI score after 3 months ‐ groin · participants with hidradenitis suppurativa
1 finding from 1 review
- no estimate extracted1 study · 22 participantsVery low
Nd:YAG laser vs topical control
Modified HS‐LASI score after 3 months ‐ inframammary · participants with hidradenitis suppurativa
1 finding from 1 review
- no estimate extracted1 study · 8 participantsVery low
Nd:YAG laser vs topical control
Percentage change in modified HS‐LASI score after 5 months compared with baseline · participants with hidradenitis suppurativa
1 finding from 1 review
- no estimate extracted1 study · 50 participantsVery low
Nd:YAG laser vs topical control
Percentage change in modified HS‐LASI score after 5 months compared with baseline ‐ axilla · participants with hidradenitis suppurativa
1 finding from 1 review
- no estimate extracted1 study · 20 participantsVery low
Nd:YAG laser vs topical control
Percentage change in modified HS‐LASI score after 5 months compared with baseline ‐ groin · participants with hidradenitis suppurativa
1 finding from 1 review
- no estimate extracted1 study · 22 participantsVery low
Adalimumab weekly vs placebo
Treatment discontinuation · participants with hidradenitis suppurativa
Adalimumab weekly showed no clear difference in frequency of treatment discontinuation compared with placebo (moderate certainty).
1 finding from 1 review
- RR 5 [0.25, 101.63]1 study · 102 participantsModerate
Niosomal methylene blue gel PDT vs free methylene blue gel PDT
HS‐LASI score · participants with hidradenitis suppurativa
1 finding from 1 review
- no estimate extracted1 study · 20 participantsLow
Staphage lysate vs placebo broth
Physician Global Assessment (Thongprasom score) · participants with hidradenitis suppurativa
Staphage lysate probably leads to higher physician global assessment compared with placebo broth (moderate certainty).
1 finding from 1 review
- RR 6.25 [1.68, 23.27]1 study · 27 participantsModerate
Adalimumab weekly vs placebo
Proportion of participants with infectious adverse effects · participants with hidradenitis suppurativa
Adalimumab weekly showed no clear difference in proportion of participants with infectious adverse effects compared with placebo (moderate certainty).
1 finding from 1 review
- RR 0.94 [0.55, 1.62]1 study · 102 participantsModerate
Adalimumab weekly vs placebo
Proportion with improvement in pain VAS · participants with hidradenitis suppurativa
Adalimumab weekly probably leads to higher proportion with improvement in pain VAS compared with placebo (moderate certainty).
1 finding from 1 review
- RR 1.77 [1.02, 3.07]1 study · 96 participantsModerate
Adalimumab weekly vs placebo
Change in modified Sartorius scale score (imputation) · participants with hidradenitis suppurativa
1 finding from 1 review
- no estimate extracted1 study · 102 participantsModerate
Adalimumab every other week vs placebo
Change in DLQI score (LOCF) · participants with hidradenitis suppurativa
1 finding from 1 review
- no estimate extracted2 studies · 124 participantsHigh
Adalimumab every other week vs placebo
Frequency of serious adverse effects · participants with hidradenitis suppurativa
Adalimumab every other week showed no clear difference in frequency of serious adverse effects compared with placebo (high certainty).
1 finding from 1 review
- RR 1.47 [0.26, 8.44]2 studies · 124 participantsHigh
Valaciclovir (short‐term) vs placebo
Viral load (shedding) in saliva · participants with recurrent herpes labialis
Valaciclovir (short‐term) showed no clear difference in viral load (shedding) in saliva compared with placebo (moderate certainty).
1 finding from 1 review
- Interventions for prevention of herpes simplex labialis (cold sores on the lips) 2015 · Cochrane Headline outcomes onlyRR 0.16 [0.02, 1.26]1 study · 120 participantsModerate
Topical 1,5‐pentanediol vs placebo
Severity (blistering, swelling, or pain) of recurrence · participants with recurrent herpes labialis
Topical 1,5‐pentanediol showed no clear difference in severity (blistering, swelling, or pain) of recurrence compared with placebo (moderate certainty).
1 finding from 1 review
- Interventions for prevention of herpes simplex labialis (cold sores on the lips) 2015 · Cochrane Headline outcomes onlyRR 1.05 [0.91, 1.2]1 study · 224 participantsModerate
Hypnotherapy vs control
Change in severity (pain) of herpes labialis · participants with recurrent herpes labialis
1 finding from 1 review
- Interventions for prevention of herpes simplex labialis (cold sores on the lips) 2015 · Cochrane Headline outcomes onlyno estimate extracted1 study · 21 participantsVery low
Hypnotherapy vs control
Change in severity (impairment of appearance) of herpes labialis · participants with recurrent herpes labialis
1 finding from 1 review
- Interventions for prevention of herpes simplex labialis (cold sores on the lips) 2015 · Cochrane Headline outcomes onlyno estimate extracted1 study · 21 participantsVery low
Ethinyl estradiol 35 μg + cyproterone acetate 2 mg vs ethinyl estradiol 30 μg + desogestrel 0.15 mg
Participant‐reported improvement of hirsutism ‐ not measured · patients with hirsutism
The review found no eligible studies for this question.
1 finding from 1 review
- Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found